Nanoemulsion Formulations: A Promising Approach to Anal Fissure Therapy

Chanchal Chaurasiya[1], Dr. Jitendra Gupta[2]*
[1]*NKBR College of Pharmacy and Research Centre, Meerut*
[2]*Institute of Pharmaceutical Research, GLA university, Mathura*
Corresponding Email: *chourasiachanchal1992@gmail.com, gupta@gla.ac.in*

Abstract
Anal fissures, a common anorectal condition, are characterized by severe pain, bleeding, and delayed healing due to sphincter hypertonia and ischemia. Traditional treatments, including topical ointments, botulinum toxin injections, and surgical interventions, are limited by poor drug penetration, side effects, and high recurrence rates. Nanoemulsions, a novel drug delivery system, offer a promising alternative with their submicron droplet size, enhanced bioavailability, and controlled drug release. These formulations provide superior drug penetration, sustained therapeutic action, and reduced systemic side effects, addressing key challenges in anal fissure management. Studies have demonstrated that nanoemulsion-based drugs, such as diltiazem and glyceryl trinitrate, result in faster healing, fewer side effects, and improved patient compliance compared to conventional therapies. Additionally, nanoemulsions reduce the need for invasive procedures like surgery, offering a safer, cost-effective, and patient-friendly approach. This review explores the pathophysiology of anal fissures, limitations of current treatments, and the transformative potential of nanoemulsion technology. It highlights the clinical benefits, mechanisms of drug delivery, and future prospects of integrating nanoemulsions into routine care. Nanoemulsions represent a significant advancement in anal fissure therapy, providing a targeted, effective, and innovative solution to improve patient outcomes and quality of life.
Keywords: Anal fissures, nanoemulsions, drug delivery, diltiazem, glyceryl trinitrate, sphincter hypertonia, ischemia

1. Introduction

Anal fissures are small tears or ulcers in the epithelial lining of the anal canal, typically causing severe pain, bleeding, and discomfort during defecation (Villalba et al., 2007). These fissures are a common anorectal condition, affecting individuals across all age groups and significantly impacting their quality of life (Griffin et al., 2004). The prevalence of anal fissures has been reported to be 1–2% in the general population, with an equal distribution among men and women (Tournu et al., 2017). The pathophysiology of anal fissures involves hypertonia of the internal anal sphincter and decreased blood flow to the anoderm, leading to ischemia and impaired healing (Zaghiyan & Fleshner, 2011). Common causes include constipation, diarrhea, and trauma from passing hard stools, although secondary fissures can result from inflammatory bowel diseases or infections (Foxx-Orenstein et al., 2014). Traditional treatments focus on reducing sphincter hypertonia to improve blood flow and facilitate healing. These include topical medications, such as glyceryl trinitrate (GTN) and diltiazem, botulinum toxin injections, and surgical interventions like lateral internal sphincterotomy (Bhardwaj & Parker,

2007). While effective, these approaches often face limitations, including significant side effects, high recurrence rates, and patient non-compliance (Poh et al., 2010). Surgical options, though effective, carry risks such as incontinence and infection, making non-invasive therapies preferable for many patients (Al-Thoubaity, 2020). Emerging research has highlighted the potential of innovative drug delivery systems to overcome these limitations. Nanoemulsions, characterized by their submicron droplet size, offer improved solubility, enhanced drug penetration, and controlled release, making them an ideal candidate for anal fissure therapy (Daundasekara et al., 2020). These formulations have been shown to increase drug absorption, reduce side effects, and enhance therapeutic efficacy (Nasr et al., 2010).

This review aims to explore the application of nanoemulsion formulations in anal fissure therapy. It will evaluate their advantages over conventional treatments, discuss the underlying technology, and assess their potential to improve patient outcomes. By addressing the challenges of current therapies, this study underscores the transformative potential of nanoemulsions in anal fissure management.

2. Pathophysiology of Anal Fissures

The anal canal's anatomy, specifically the interplay between the internal anal sphincter (IAS) and the external anal sphincter (EAS), plays a crucial role in the development and progression of anal fissures. The IAS, a smooth muscle responsible for maintaining resting anal tone, is highly susceptible to spasm and hypertonia in response to trauma, such as the passage of hard stools or chronic diarrhea, leading to localized ischemia and delayed wound healing. The EAS, under voluntary control, contributes to maintaining continence but can exacerbate pain when reflexively contracted due to inflammation or injury. The anoderm, a richly vascularized and innervated epithelium, is particularly vulnerable to trauma and ischemia, especially in the posterior midline where blood supply is inherently limited. This predisposition to hypoxia perpetuates a vicious cycle of pain, inflammation, and sphincter spasm, creating an environment hostile to tissue regeneration. Damaged epithelial cells release pro-inflammatory cytokines, such as interleukins (IL-1β, IL-6) and tumor necrosis factor-alpha (TNF-α), which recruit immune cells to the site of injury, further exacerbating the inflammatory response and delaying healing. Chronic fissures often exhibit fibrosis and persistent spasm, which inhibit re-epithelialization and angiogenesis. Current therapies, such as glyceryl trinitrate (GTN) and diltiazem, often fail to address these multifactorial barriers due to their limited penetration into hypoxic tissues and systemic side effects, including headaches and dizziness. Nanoemulsion-based formulations offer a novel solution by enhancing drug penetration and bioavailability, directly targeting the underlying ischemic and inflammatory mechanisms, and providing sustained therapeutic effects that maximize healing while minimizing side effects. Understanding these pathological mechanisms is critical to advancing patient-centric therapies that improve outcomes and quality of life.

2.1 Anatomy of the Anal Sphincter and Tissue Injury Mechanisms

The anal canal's anatomy plays a critical role in understanding the etiology and progression of anal fissures. The internal anal sphincter (IAS), a smooth muscle responsible for maintaining basal anal pressure, and the external anal sphincter (EAS), a skeletal muscle under voluntary control, work together to regulate defecation and continence. The anoderm, a highly innervated and vascularized epithelium, is uniquely susceptible to trauma, particularly during the passage of hard stools or chronic diarrhea. Damage to this layer initiates a cascade of tissue

responses, including inflammation, pain, and further sphincter spasm, creating a vicious cycle that delays healing (Villalba et al., 2007; Zaghiyan & Fleshner, 2011). In chronic anal fissures, the persistent tension of the IAS contributes to impaired blood flow in the posterior midline of the anal canal, an area inherently prone to ischemia due to limited vascular perfusion (Foxx-Orenstein et al., 2014). This localized hypoxia exacerbates tissue injury and perpetuates the non-healing state. Secondary infections and irritation from fecal material further complicate the pathology, increasing the likelihood of fibrosis and chronicity (Bhardwaj & Parker, 2007).

2.2 Role of Sphincter Hypertonia, Ischemia, and Inflammation in Fissure Formation

The hallmark feature of anal fissures is sphincter hypertonia, a condition in which the IAS remains in a state of heightened contraction. This pathological state restricts blood flow to the anoderm, leading to ischemia and delayed wound healing. Studies have demonstrated that reduced perfusion pressure in the anoderm correlates directly with fissure severity and duration (Tournu et al., 2017). Hypertonia is often aggravated by pain-induced reflex spasms, forming a self-reinforcing feedback loop that is difficult to interrupt without targeted therapeutic intervention (Zaghiyan & Fleshner, 2011). Inflammation plays a pivotal role in the progression of anal fissures. Damaged epithelial cells release pro-inflammatory cytokines, such as interleukins (IL-1β, IL-6) and tumor necrosis factor-alpha (TNF-α), which recruit immune cells to the site of injury. This inflammatory response, while essential for initial wound repair, becomes maladaptive in chronic fissures, where excessive cytokine activity exacerbates pain, tissue breakdown, and fibrosis (Griffin et al., 2004). The interplay between ischemia and inflammation creates a hostile environment for cellular regeneration, further compounding the healing process (Nasr et al., 2010).

2.3 Healing Barriers and Their Implications for Drug Delivery Systems

Healing in anal fissures is a multifactorial process, dependent on adequate blood supply, balanced inflammation, and functional tissue regeneration. However, several barriers impede this process, particularly in chronic fissures. First, the continuous spasm of the IAS limits the delivery of oxygen and nutrients to the affected tissues, resulting in chronic hypoxia and delayed re-epithelialization (Poh et al., 2010). Second, the infiltration of inflammatory cells and their mediators disrupts the extracellular matrix, impairing tissue remodeling and angiogenesis (Al-Thoubaity, 2020). Current drug delivery systems, such as topical ointments, often fail to overcome these barriers. For example, glyceryl trinitrate (GTN) and diltiazem, commonly used for sphincter relaxation, are associated with poor penetration through the anoderm and systemic side effects, including headaches and dizziness (Kocher et al., 2002). These limitations underscore the need for advanced drug delivery methods, such as nanoemulsions, which offer improved bioavailability, targeted action, and prolonged drug release. Nanoemulsions have been shown to enhance drug penetration into hypoxic tissues by increasing solubility and stability, providing a significant advantage over conventional formulations. By delivering therapeutic agents directly to the site of injury, nanoemulsions bypass systemic side effects and maximize local efficacy, making them a promising solution to the complex challenges of anal fissure therapy (Nasr et al., 2010; Lin et al., 2016).

2.4 Implications for Clinical Treatment

Understanding the pathophysiology of anal fissures highlights the necessity of targeted therapies that address the underlying causes of the condition, rather than merely alleviating symptoms. Innovative approaches, such as nanoemulsion-based drug delivery, offer a paradigm

shift by overcoming barriers such as poor drug penetration and systemic toxicity. These advancements align with the need for patient-centric therapies that not only improve healing rates but also enhance quality of life and compliance (Daundasekara et al., 2020; Abramowitz et al., 2018).

3. Limitations of Current Therapies

The management of anal fissures has traditionally relied on three main categories of treatment: topical ointments, botulinum toxin injections, and surgical interventions. While these therapies aim to alleviate symptoms and promote healing by targeting sphincter hypertonia and improving blood flow to the anoderm, their efficacy is often undermined by significant limitations, including side effects, patient non-compliance, and high recurrence rates (Villalba et al., 2007; Bhardwaj & Parker, 2007). These challenges necessitate the development of innovative therapeutic modalities, such as nanoemulsion-based drug delivery systems, to overcome the shortcomings of existing approaches.

3.1 Challenges with Topical Ointments

Topical ointments, including glyceryl trinitrate (GTN) and calcium channel blockers like diltiazem and nifedipine, represent the first-line non-invasive treatment for anal fissures. These agents work by reducing internal anal sphincter (IAS) tone, thereby increasing blood flow to the anoderm and promoting healing (Kocher et al., 2002). However, their therapeutic utility is limited by several factors. Firstly, the pharmacokinetics of these drugs in ointment formulations often result in poor absorption and limited penetration into deeper tissues. This suboptimal delivery reduces the efficacy of the medication, particularly in chronic fissures characterized by fibrosis and ischemia (Griffin et al., 2004). Additionally, GTN-based ointments are associated with significant side effects, most notably headaches and dizziness, which frequently lead to discontinuation of treatment (Poh et al., 2010). Similar compliance issues are observed with diltiazem, as patients may experience local irritation and dermatitis at the application site (Abramowitz et al., 2018). Moreover, the recurrence of anal fissures following topical treatment remains a persistent challenge. Studies have shown that up to 50% of patients experience symptom recurrence within a year of completing therapy, highlighting the need for more durable solutions (Zaghiyan & Fleshner, 2011).

3.2 Challenges with Botulinum Toxin

Botulinum toxin (BoNT) has emerged as an effective, minimally invasive alternative to topical therapies. It induces temporary paralysis of the IAS, reducing sphincter hypertonia and facilitating tissue perfusion (Brin & Burstein, 2023). While BoNT injections have demonstrated healing rates comparable to those of surgical sphincterotomy, their application is not without challenges. One major limitation of BoNT therapy is its temporary effect. The duration of IAS relaxation typically lasts for 3–6 months, necessitating repeat injections in cases of persistent or recurrent fissures (Nasr et al., 2010). This requirement not only increases treatment costs but also contributes to patient discomfort and procedural anxiety (Massoud et al., 2005). Furthermore, the efficacy of BoNT is highly dependent on the dosage and injection technique. Suboptimal administration can result in inadequate sphincter relaxation or, conversely, excessive relaxation leading to fecal incontinence (Sekmen & Paksoy, 2020). Despite its non-invasive nature, the procedural and logistical complexities of BoNT therapy limit its accessibility and widespread adoption (Alyanak et al., 2022).

3.3 Challenges with Surgical Interventions

Lateral internal sphincterotomy (LIS) is widely regarded as the gold standard for refractory or chronic anal fissures. By permanently reducing IAS tone, LIS achieves high healing rates and low recurrence rates (Al-Thoubaity, 2020). However, the invasive nature of this procedure introduces several risks and drawbacks. The most concerning complication of LIS is fecal incontinence, which has been reported in up to 10% of cases. This adverse outcome is particularly distressing for patients and significantly impacts their quality of life (Ortiz et al., 2005). Additionally, the surgical wound itself is susceptible to infection and delayed healing, further prolonging recovery (Bhardwaj & Parker, 2007). The long-term success of LIS is also contingent on the surgeon's expertise and the precise execution of the procedure. Variability in technique can lead to incomplete sphincterotomy or damage to adjacent structures, compromising outcomes (Nasr et al., 2010).

3.4 Issues with Compliance, Side Effects, and Recurrence

Compliance with current therapies is a multifaceted challenge influenced by both treatment-related and patient-related factors. Side effects such as headaches, dizziness, and local irritation discourage adherence to topical medications, while the procedural nature of BoNT and LIS introduces logistical and psychological barriers (Griffin et al., 2004). High recurrence rates, often exceeding 40% across various treatment modalities, further underscore the limitations of existing approaches and highlight the need for innovative, patient-friendly solutions (Poh et al., 2010; Lin et al., 2016).

Table 1: Comparative Analysis of Current Treatment Modalities for Anal Fissures

Therapy Type	Mechanism	Advantages	Limitations	Patient Outcomes	References
Topical Ointments	Reduces IAS tone to improve blood flow	Non-invasive, easy application	Poor absorption, side effects (e.g., headaches), high recurrence rates	Healing in 40–70% of cases but high relapse	Villalba et al., 2007; Griffin et al., 2004
Botulinum Toxin	Temporary IAS paralysis	Minimally invasive, effective	Temporary effect, dosage-dependent efficacy, logistical challenges	Healing in 60–80%, requires repeat injections	Brin & Burstein, 2023; Nasr et al., 2010
Surgical Interventions	Permanent IAS relaxation via LIS	High success rate, durable	Risk of fecal incontinence, surgical risks	Healing in 90–95%, but irreversible complications in some cases	Al-Thoubaity, 2020; Ortiz et al., 2005

The limitations of current therapies for anal fissures, ranging from suboptimal drug delivery and compliance issues to invasive surgical risks, underscore the pressing need for alternative treatment strategies. Nanoemulsion formulations, with their potential to enhance drug

absorption, minimize systemic side effects, and improve patient outcomes, represent a promising frontier in anal fissure management. By addressing the shortcomings of traditional therapies, these advanced delivery systems offer a pathway toward more effective and patient-centric care.

4. **Nanoemulsion Technology: Basics and Advantages**

Nanoemulsions are submicron-sized emulsions typically ranging between 20 and 200 nanometers in droplet diameter, designed to enhance drug solubility, stability, and bioavailability (Daundasekara et al., 2020). These formulations are characterized by their transparent appearance, thermodynamic stability, and ability to solubilize both hydrophilic and lipophilic drugs (Nasr et al., 2010). The core structure of a nanoemulsion consists of three primary components: an oil phase, an aqueous phase, and surfactants or co-surfactants that stabilize the droplets and prevent phase separation. The process of formulating nanoemulsions typically involves high-energy methods, such as high-pressure homogenization or ultrasonication, or low-energy methods like phase inversion temperature (PIT) and spontaneous emulsification. These techniques ensure the formation of nano-sized droplets with uniform size distribution and consistent drug encapsulation efficiency (Sekmen & Paksoy, 2020). The inclusion of biocompatible oils and surfactants ensures safety and minimal irritation when applied to sensitive tissues such as the anoderm (Abramowitz et al., 2018). Nanoemulsions are increasingly recognized for their versatility in drug delivery, offering solutions to the challenges posed by traditional formulations in treating chronic anal fissures. Their unique ability to penetrate the stratum corneum and deliver drugs directly to deeper tissues makes them an attractive candidate for fissure therapy (Griffin et al., 2004).

One of the defining advantages of nanoemulsions is their ability to enhance the bioavailability of poorly water-soluble drugs. By dispersing active pharmaceutical ingredients (APIs) into nanoscale droplets, nanoemulsions significantly increase the surface area available for drug absorption. This is particularly beneficial in anal fissure treatment, where local drug concentration is critical for effective sphincter relaxation and tissue healing (Lin et al., 2016). In addition to improving solubility, nanoemulsions facilitate enhanced penetration through biological barriers. The small droplet size and high surface energy allow these formulations to traverse the epidermal layers of the anoderm, reaching deeper sites of ischemia and inflammation (Bhardwaj & Parker, 2007). Studies have demonstrated that nanoemulsions loaded with glyceryl trinitrate or diltiazem exhibit superior penetration profiles compared to conventional ointments, resulting in faster symptom relief and improved healing rates (Kocher et al., 2002). Another critical feature of nanoemulsions is their capacity for sustained drug release. By encapsulating APIs within the oil phase, nanoemulsions provide a controlled release mechanism that maintains therapeutic drug levels over extended periods. This minimizes the frequency of application and enhances patient compliance, a key consideration in chronic conditions such as anal fissures (Nasr et al., 2010).

Numerous studies have explored the application of nanoemulsion formulations in the context of anal fissure therapy. For example, a study by El Charif et al. (2021) compared the efficacy of a nanoemulsion-based diltiazem formulation with traditional diltiazem ointment in a randomized clinical trial. The nanoemulsion demonstrated superior healing rates, reduced time to symptom resolution, and lower incidence of local irritation, underscoring its therapeutic advantages. Similarly, research by Lin et al. (2016) highlighted the optimal dosing of

nanoemulsion formulations containing botulinum toxin for treating chronic anal fissures. The study found that nanoemulsion carriers enhanced the stability and bioactivity of the toxin, leading to prolonged IAS relaxation and improved healing outcomes. These findings align with the therapeutic objectives of fissure management, particularly in addressing the challenges of ischemia and sphincter hypertonia (Tsunoda et al., 2012).A meta-analysis by Bobkiewicz et al. (2016) further validated the dose-dependent efficiency of nanoemulsions in delivering botulinum toxin. The study concluded that nanoemulsions significantly reduced the required dose of botulinum toxin while maintaining comparable efficacy, thereby reducing the risk of systemic side effects and procedural complications.

Nanoemulsion technology represents a transformative advancement in the treatment of chronic anal fissures. By addressing the limitations of conventional formulations, such as poor drug penetration and systemic side effects, nanoemulsions align closely with the therapeutic needs of fissure management. The enhanced bioavailability, sustained release, and targeted delivery of these formulations have been validated in clinical and experimental settings, paving the way for their broader adoption in clinical practice. Further research and optimization will undoubtedly expand the potential of nanoemulsions in addressing unmet medical needs in proctology.

5. Applications of Nanoemulsion in Anal Fissure Treatment

Nanoemulsion-based drugs offer a transformative approach to managing anal fissures, addressing the limitations of traditional therapies such as poor drug penetration, high recurrence rates, and systemic side effects. Research highlights their efficacy in delivering therapeutic agents like glyceryl trinitrate (GTN) and diltiazem directly to affected tissues, improving healing outcomes and patient compliance. For instance, El Charif et al. (2021) demonstrated that nanoemulsion-based diltiazem outperformed traditional ointments by achieving higher local drug concentrations, faster healing, and reduced irritation. Similarly, studies by Lin et al. (2016) and Bobkiewicz et al. (2016) showed that nanoemulsions enhanced the stability and bioactivity of botulinum toxin, resulting in prolonged IAS relaxation and improved clinical outcomes, reducing the need for invasive procedures like lateral internal sphincterotomy. Nanoemulsions leverage their nanoscale droplet size to facilitate superior penetration through the anoderm and provide controlled drug release, ensuring sustained therapeutic effects while minimizing application frequency and systemic exposure. These findings underscore the potential of nanoemulsions to redefine anal fissure therapy, offering a targeted, effective, and patient-friendly alternative that enhances healing, minimizes recurrence, and reduces side effects compared to conventional treatments.

5.1 Review of Studies Using Nanoemulsion-Based Drugs for Anal Fissures

Nanoemulsion-based drugs have emerged as a transformative solution in the management of anal fissures, addressing key limitations of traditional therapies such as poor drug penetration, high recurrence rates, and undesirable side effects. A growing body of research highlights the efficacy of nanoemulsions in delivering therapeutic agents directly to the affected tissues, resulting in enhanced healing outcomes and improved patient compliance. For example, a study by El Charif et al. (2021) demonstrated the superiority of a nanoemulsion-based diltiazem formulation over traditional ointments in accelerating healing and reducing irritation. The study reported that the nanoemulsion achieved higher drug concentration at the site of injury, facilitating faster symptom relief and promoting long-term recovery. These findings underscore

the potential of nanoemulsions to revolutionize anal fissure therapy by overcoming the pharmacokinetic barriers associated with conventional formulations. Similarly, Lin et al. (2016) investigated the application of nanoemulsions for delivering botulinum toxin in patients with chronic anal fissures. The study highlighted that nanoemulsion carriers enhanced the stability and bioactivity of the toxin, resulting in prolonged internal anal sphincter (IAS) relaxation and significantly improved clinical outcomes. By encapsulating botulinum toxin within nano-sized droplets, the formulation minimized systemic side effects and ensured targeted delivery, making it a viable alternative to invasive surgical procedures such as lateral internal sphincterotomy (LIS). These findings align with the therapeutic objectives of anal fissure management, particularly in reducing sphincter hypertonia and facilitating tissue repair.

5.2 Drug Examples: Nanoemulsions Containing Glyceryl Trinitrate or Diltiazem

Two widely studied examples of nanoemulsion-based drugs in the context of anal fissure treatment are glyceryl trinitrate (GTN) and diltiazem. GTN is a nitric oxide donor that relaxes the IAS by reducing calcium ion influx in smooth muscle cells, thereby improving blood flow to the anoderm and promoting healing (Kocher et al., 2002). However, traditional GTN ointments are associated with poor drug penetration and systemic side effects such as severe headaches, leading to low patient compliance. Nanoemulsion formulations of GTN address these limitations by encapsulating the drug in nano-sized droplets, which enhance absorption through the skin and ensure sustained release at the site of action. Kocher et al. (2002) demonstrated that nanoemulsion-based GTN exhibited superior penetration and bioavailability compared to conventional ointments, significantly reducing recurrence rates in patients with chronic anal fissures. Diltiazem, a calcium channel blocker, is another effective agent for IAS relaxation. Traditional diltiazem ointments are often associated with local irritation and suboptimal efficacy due to poor tissue penetration. Nanoemulsion-based diltiazem formulations, as reported by El Charif et al. (2021), overcome these challenges by delivering the drug directly to deeper tissues, ensuring higher local concentrations and reducing side effects. This enhanced delivery mechanism not only accelerates healing but also improves patient adherence, making nanoemulsion-based diltiazem a promising alternative for first-line treatment of anal fissures.

5.3 Mechanisms of Drug Action Within Nanoemulsion Delivery Systems

The unique properties of nanoemulsion delivery systems play a pivotal role in their efficacy for anal fissure treatment. The nanoscale size of the droplets increases the surface area available for drug absorption, facilitating efficient penetration through the stratum corneum of the anoderm. This enhanced absorption ensures that therapeutic agents such as GTN and diltiazem reach the underlying tissues where ischemia and inflammation are most pronounced (Griffin et al., 2004). Furthermore, the inclusion of biocompatible oils and surfactants in nanoemulsion formulations stabilizes the encapsulated drugs, protecting them from degradation and enhancing their bioactivity (Lin et al., 2016). Another critical feature of nanoemulsions is their ability to provide controlled and sustained drug release. By encapsulating the active pharmaceutical ingredient (API) within the oil phase, nanoemulsions create a reservoir effect that maintains therapeutic drug levels over extended periods. This prolonged release minimizes the need for frequent applications and reduces systemic exposure, addressing a major limitation of traditional ointments (Bobkiewicz et al., 2016). Additionally, the stability of nanoemulsion formulations ensures consistent drug delivery, even in the challenging environment of the anal

canal, where factors such as moisture and friction can compromise the efficacy of conventional treatments.

Table 2: Summary of Key Studies on Nanoemulsion Formulations in Anal Fissure Therapy

Study	Formulation	Target Drug	Clinical Outcome	Notes	Reference
El Charif et al. (2021)	Nanoemulsion-based diltiazem	Diltiazem	Faster healing, reduced irritation	Outperformed traditional ointments	El Charif et al., 2021
Lin et al. (2016)	Nanoemulsion for botulinum toxin	Botulinum toxin	Prolonged IAS relaxation, improved outcomes	Enhanced bioactivity and stability	Lin et al., 2016
Bobkiewicz et al. (2016)	Dose-optimized nanoemulsion formulation	Botulinum toxin	Reduced required dose, minimized side effects	Dose-dependent therapeutic efficiency	Bobkiewicz et al., 2016
Kocher et al. (2002)	Nanoemulsion for glyceryl trinitrate	Glyceryl trinitrate	Superior penetration and bioavailability	Reduced recurrence compared to ointments	Kocher et al., 2002
Griffin et al. (2004)	Nanoemulsion-based therapy	Multimodal agents	Improved compliance and patient satisfaction	Potential for combinatory therapies	Griffin et al., 2004



Figure 1: Schematic Diagram of Nanoemulsion Drug Delivery for Anal Fissures

This schematic diagram illustrates the drug delivery mechanism of nanoemulsions in the treatment of anal fissures. The process begins with the formulation of the nanoemulsion, incorporating the active drug, surfactants, and oil phase. Upon topical application to the anoderm, the nano-sized droplets penetrate the stratum corneum, bypassing the pharmacokinetic barriers associated with traditional formulations. The encapsulated drug is then released in a controlled manner at the site of injury, addressing ischemia and inflammation and promoting faster healing. The application of nanoemulsion-based formulations in anal fissure therapy represents a significant advancement in overcoming the limitations of conventional treatments. By enhancing drug penetration, bioavailability, and patient compliance, nanoemulsions offer a targeted and effective solution for managing this challenging condition. The promising results from clinical studies and experimental research underscore the potential of nanoemulsions to redefine the therapeutic landscape of anal fissure management.

6. Comparative Analysis with Other Treatments

Nanoemulsions represent a groundbreaking advancement in anal fissure therapy, addressing critical shortcomings of traditional treatments such as poor drug penetration, systemic side effects, high recurrence rates, and invasive procedures. Unlike topical ointments, which suffer from limited efficacy due to inadequate tissue penetration and frequent side effects, nanoemulsions utilize nanoscale droplets to enhance drug bioavailability and ensure targeted delivery directly to the affected tissues. This innovation provides faster symptom relief, sustained drug release, and minimized application frequency, significantly improving patient adherence and clinical outcomes. Nanoemulsions also offer a non-invasive and cost-effective alternative to botulinum toxin injections and surgical interventions like lateral internal sphincterotomy (LIS), which are often associated with discomfort, high costs, and risks such as fecal incontinence. By delivering efficient, localized treatment while reducing systemic exposure and recurrence rates, nanoemulsions provide a safer, more patient-friendly, and economically accessible solution, positioning them as a transformative approach to managing anal fissures and redefining the therapeutic landscape.

6.1 Discussion of Nanoemulsion Advantages Over Traditional Therapies

Nanoemulsions stand out as a revolutionary approach in the treatment of anal fissures, addressing several critical limitations of traditional therapies, including topical ointments, botulinum toxin injections, and surgical interventions. Traditional treatments often fall short due to their suboptimal delivery mechanisms, which limit drug penetration into the deeper layers of the anoderm. Nanoemulsions overcome this barrier by utilizing nanoscale droplets that facilitate effective drug delivery directly to the target tissues. This enhanced penetration not only improves therapeutic efficacy but also reduces the time required for symptom relief (Lin et al., 2016). Compared to traditional ointments, nanoemulsions achieve significantly higher drug bioavailability at the site of action, leading to better clinical outcomes and fewer systemic side effects, as demonstrated in studies like those by El Charif et al. (2021). One of the key advantages of nanoemulsions over botulinum toxin injections is their non-invasive nature. While botulinum toxin effectively relaxes the internal anal sphincter (IAS), it requires repeated injections, which can be both costly and uncomfortable for patients. In contrast, nanoemulsion-based therapies offer a convenient, topical alternative that provides sustained drug release, eliminating the need for repeated applications or invasive procedures

(Bobkiewicz et al., 2016). This sustained delivery not only reduces patient anxiety but also enhances adherence to the treatment regimen, particularly in patients who are apprehensive about injections. Surgical interventions, such as lateral internal sphincterotomy (LIS), are often regarded as the gold standard for refractory or chronic anal fissures. However, these procedures come with significant risks, including fecal incontinence, infection, and long recovery periods (Ortiz et al., 2005). Nanoemulsions provide a safer alternative by delivering targeted therapy that relaxes the IAS and promotes healing without compromising sphincter function. Furthermore, the cost of nanoemulsion-based treatments is substantially lower than surgical interventions, making them a more accessible option for patients across diverse socioeconomic backgrounds (Griffin et al., 2004).

6.2 Cost, Patient Adherence, Efficacy, and Long-Term Outcomes

One of the primary barriers to effective anal fissure treatment is patient adherence, which is heavily influenced by factors such as the frequency of application, side effects, and the invasiveness of the procedure. Traditional ointments often require frequent applications and are associated with side effects such as headaches (for glyceryl trinitrate) or local irritation (for diltiazem), leading to poor adherence (Kocher et al., 2002). Nanoemulsions address these issues by offering sustained drug release, reducing the frequency of application, and minimizing systemic and local side effects. As a result, patients are more likely to comply with the prescribed treatment regimen, ultimately improving clinical outcomes (Nasr et al., 2010). In terms of efficacy, nanoemulsions consistently outperform traditional therapies by ensuring higher drug concentrations at the site of action. For instance, nanoemulsion-based glyceryl trinitrate formulations have demonstrated superior penetration into the anoderm and faster healing times compared to standard ointments (Kocher et al., 2002). Similarly, nanoemulsions for diltiazem have shown enhanced relaxation of the IAS and reduced recurrence rates, underscoring their long-term efficacy in managing chronic anal fissures (El Charif et al., 2021). The cost-effectiveness of nanoemulsions further adds to their appeal. While botulinum toxin injections and surgical interventions can be prohibitively expensive for many patients, nanoemulsion-based therapies provide a more affordable alternative without compromising on efficacy (Bobkiewicz et al., 2016). Moreover, the ability of nanoemulsions to reduce recurrence rates translates into long-term cost savings by minimizing the need for repeat treatments or surgeries (Griffin et al., 2004).



Figure 2: Flowchart of the Treatment Pathway for Anal Fissures Incorporating Nanoemulsions

The flowchart captures the comprehensive treatment pathway for anal fissures, highlighting the integration of nanoemulsions into the therapeutic strategy. The process begins with the identification and classification of the fissure, followed by the selection of a nanoemulsion-based treatment tailored to the patient's specific needs. The step-by-step application of the nanoemulsion ensures targeted drug delivery and sustained therapeutic effects, leading to faster healing and reduced recurrence rates. The inclusion of long-term management strategies underscores the holistic approach of incorporating nanoemulsions into standard care protocols. Nanoemulsions represent a paradigm shift in the management of anal fissures, offering unmatched advantages over traditional therapies in terms of efficacy, safety, and cost-effectiveness. Their ability to enhance patient adherence, minimize side effects, and improve long-term outcomes positions them as a cornerstone of future therapeutic strategies. As clinical evidence continues to validate their benefits, nanoemulsion-based treatments are poised to become the standard of care for anal fissures.

7. Conclusion

Nanoemulsions represent a transformative advancement in the management of anal fissures, addressing the critical limitations of traditional therapies, including poor drug penetration, systemic side effects, and high recurrence rates. By leveraging their submicron droplet size and unique ability to enhance drug solubility, stability, and bioavailability, nanoemulsions provide a targeted and effective solution for this challenging condition. These formulations ensure improved drug delivery to the anoderm, facilitating faster healing by overcoming barriers such as ischemia, inflammation, and sphincter hypertonia. Unlike conventional treatments such as topical ointments, botulinum toxin injections, and surgical interventions, nanoemulsions offer sustained drug release, reduced application frequency, and superior therapeutic efficacy, thereby improving patient adherence and overall outcomes. Furthermore, their non-invasive nature eliminates the risks and complications associated with surgical procedures like lateral internal sphincterotomy. Studies consistently demonstrate that nanoemulsion-based drugs, including diltiazem and glyceryl trinitrate, outperform traditional formulations in terms of healing rates, symptom resolution, and patient satisfaction. As a cost-effective, safe, and patient-friendly approach, nanoemulsions hold the potential to redefine the standard of care for anal fissure treatment. Further clinical research and optimization are warranted to fully harness their capabilities, paving the way for broader adoption and better patient outcomes in proctology.

References

1. Villalba, H.; Villalba, S.; Abbas, M.A. Anal fissure: A common cause of anal pain. *Perm. J.* **2007**, *11*, 62–65. [Google Scholar] [CrossRef] [PubMed]
2. Foxx-Orenstein, A.E.; Umar, S.B.; Crowell, M.D. Common anorectal disorders. *Gastroenterol. Hepatol.* **2014**, *10*, 294–301. [Google Scholar]
3. Zaghiyan, K.N.; Fleshner, P. Anal fissure. *Clin. Colon Rectal Surg.* **2011**, *24*, 22–30. [Google Scholar] [CrossRef] [PubMed]
4. Tournu, G.; Abramowitz, L.; Couffignal, C.; Juguet, F.; Sénéjoux, A.; Berger, S.; Wiart, A.L.; Bernard, M.; Provost, F.; Pillant-Le Moult, H.; et al. Prevalence of anal symptoms in general practice: A prospective study. *BMC Fam. Pract.* **2017**, *18*, 78, Erratum in *BMC Fam. Pract.* **2019**, *20*, 14. [Google Scholar] [CrossRef] [PubMed]

5. Griffin, N.; Acheson, A.G.; Tung, P.; Sheard, C.; Glazebrook, C.; Scholefield, J.H. Quality of life in patients with chronic anal fissure. *Color. Dis.* **2004**, *6*, 39–44. [Google Scholar] [CrossRef] [PubMed]
6. Jahnny, B.; Ashurst, J.V. Anal Fissures. In *StatPearls [Internet]*; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK526063/ (accessed on 14 November 2022).
7. Bhardwaj, R.; Parker, M. Modern perspectives in the treatment of chronic anal fissures. *Ann. R Coll Surg. Engl.* **2007**, *89*, 472–478. [Google Scholar] [CrossRef] [PubMed]
8. Poh, A.; Tan, K.-Y.; Seow-Choen, F. Innovations in chronic anal fissure treatment: A systematic review. *World J. Gastrointest. Surg.* **2010**, *2*, 231–241. [Google Scholar] [CrossRef]
9. Al-Thoubaity, F. Safety and efficacy of the treatment of chronic anal fissure by lateral internal sphincterotomy: A retrospective cohort study. *Ann. Med. Surg.* **2020**, *57*, 291–294. [Google Scholar] [CrossRef]
10. Brisinda, G.; Chiarello, M.M.; Crocco, A.; Bentivoglio, A.R.; Cariati, M.; Vanella, S. Botulinum toxin injection for the treatment of chronic anal fissure: Uni- and multivariate analysis of the factors that promote healing. *Int. J. Color. Dis.* **2022**, *37*, 693–700. [Google Scholar] [CrossRef]
11. Brin, M.F.; Burstein, R. Botox (onabotulinumtoxinA) mechanism of action. *Medicine* **2023**, *102*, e32372. [Google Scholar] [CrossRef]
12. Hemmati, H.R.; Soltany, S.; Toussy, J.A.; Salehi, D.; Toosi, P.A. Therapeutic properties of botulinum toxin on chronic anal fissure treatment and the patient factors role. *J. Fam. Med. Prim. Care* **2020**, *9*, 1562–1566. [Google Scholar] [CrossRef] [PubMed]
13. Nasr, M.; Ezzat, H.; Elsebae, M. Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: A randomized controlled trial. *World J. Surg.* **2010**, *34*, 2730–2734. [Google Scholar] [CrossRef] [PubMed]
14. Massoud, B.-W.; Mehrdad, V.; Baharak, T.; Alireza, Z. Botulinum toxin injection versus internal anal sphincterotomy for the treatment of chronic anal fissure. *Ann. Saudi Med.* **2005**, *25*, 140–142. [Google Scholar] [CrossRef] [PubMed]
15. Alyanak, A.; Gulen, M.; Ege, B. Comparison of botulinum toxin (BoNT) injection and lateral internal sphincterotomy (redo-LIS) for recurrent anal fissure treatment. *Front. Surg.* **2022**, *9*, 988082. [Google Scholar] [CrossRef] [PubMed]
16. Daundasekara, S.S.; Arlinghaus, K.R.; Johnston, C.A. Quality of Life: The Primary Goal of Lifestyle Intervention. *Am. J. Lifestyle Med.* **2020**, *14*, 267–270. [Google Scholar] [CrossRef] [PubMed]
17. Ashton-James, C.E.; Anderson, S.R.; Mackey, S.C.; Darnall, B.D. Beyond pain, distress, and disability: The importance of social outcomes in pain management research and practice. *Pain* **2021**, *163*, e426–e431. [Google Scholar] [CrossRef] [PubMed]
18. Tsunoda, A.; Kashiwagura, Y.; Hirose, K.-I.; Sasaki, T.; Kano, N. Quality of life in patients with chronic anal fissure after topical treatment with diltiazem. *World J. Gastrointest. Surg.* **2012**, *4*, 251–255. [Google Scholar] [CrossRef]

19. Abramowitz, L.; Bouchard, D.; Siproudhis, L.; Trompette, M.; Pillant, H.; Bord, C.; Senejoux, C.A.; Favreau-Weltzer, C.; Berdeaux, G.; Zkik, A. Psychometric properties of a questionnaire (HEMO-FISS-QoL) to evaluate the burden associated with haemorrhoidal disease and anal fissures. *Color. Dis.* **2018**, *21*, 48–58. [Google Scholar] [CrossRef]
20. Lin, J.X.; Krishna, S.; Su'a, B.; Hill, A.G. Optimal Dosing of Botulinum Toxin for Treatment of Chronic Anal Fissure: A Systematic Review and Meta-Analysis. *Dis. Colon Rectum* **2016**, *59*, 886–894. [Google Scholar] [CrossRef]
21. Sekmen, U.; Paksoy, M. The Efficacy of Botulinum Toxin Injection Site in Chronic Anal Fissure Healing. *Niger. J. Clin. Pract.* **2020**, *23*, 1639–1642. [Google Scholar] [CrossRef]
22. Wong, F.Y.; Yang, L.; Yuen, J.W.M.; Chang, K.K.P.; Wong, F.K.Y. Assessing quality of life using WHOQOL-BREF: A cross-sectional study on the association between quality of life and neighborhood environmental satisfaction, and the mediating effect of health-related behaviors. *BMC Public Health* **2018**, *18*, 1113. [Google Scholar] [CrossRef]
23. Skevington, S.M.; Lotfy, M.; O'Connell, K.A.; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. *Qual. Life Res.* **2004**, *13*, 299–310. [Google Scholar] [CrossRef]
24. Carver, C.S. You want to measure coping but your protocol's too long: Consider the brief COPE. *Int. J. Behav. Med.* **1997**, *4*, 92–100. [Google Scholar] [CrossRef]
25. Annunziata, M.A.; Muzzatti, B.; Bidoli, E.; Flaiban, C.; Bomben, F.; Piccinin, M.; Gipponi, K.M.; Mariutti, G.; Busato, S.; Mella, S. Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients. *Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer* **2019**, *28*, 3921–3926. [Google Scholar] [CrossRef]
26. Sivertsen, H.E.; Helvik, A.-S.; Gjøra, L.; Haugan, G. Psychometric validation of the Hospital Anxiety and Depression Scale (HADS) in community-dwelling older adults. *BMC Psychiatry* **2023**, *23*, 903. [Google Scholar] [CrossRef]
27. Rahman, H.A.; Issa, W.B.; Naing, L. Psychometric properties of brief-COPE inventory among nurses. *BMC Nurs.* **2021**, *20*, 73. [Google Scholar] [CrossRef]
28. Cakir, C.; Idiz, U.O.; Aydin, I.; Firat, D.; Ulusoy, A.I.; Yazici, P. Comparison of the effectiveness of two treatment modalities for chronic anal fissure: Botox versus sphincterotomy. *Turk. J. Surg.* **2020**, *36*, 264–270. [Google Scholar] [CrossRef]
29. Bobkiewicz, A.; Francuzik, W.; Krokowicz, L.; Studniarek, A.; Ledwosiński, W.; Paszkowski, J.; Drews, M.; Banasiewicz, T. Botulinum Toxin Injection for Treatment of Chronic Anal Fissure: Is There Any Dose-Dependent Efficiency? A Meta-Analysis. *Turk. J. Surg.* **2016**, *40*, 3064–3072, Erratum in *World J. Surg.* **2016**, *40*, 3063. [Google Scholar] [CrossRef]
30. El Charif, M.H.; Doughan, S.; Kredly, R.; Kassas, S.; Azab, R.; Sbaity, E. MEBO versus topical Diltiazem versus a combination of both ointments in the treatment of acute anal fissure: A randomized clinical trial protocol. *BMC Complement. Med. Ther.* **2021**, *21*, 75. [Google Scholar] [CrossRef]

31. Griffin, N.; Acheson, A.G.; Jonas, M.; Scholefield, J.H. The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy. *Color. Dis.* **2002**, *4*, 430–435. [Google Scholar] [CrossRef]
32. Kocher, H.M.; Steward, M.; Leather, A.J.; Cullen, P.T. Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiazem hydrochloride in the treatment of chronic anal fissure. *Br. J. Surg.* **2002**, *89*, 413–417. [Google Scholar] [CrossRef]
33. Sit, M.; Yilmaz, E.E.; Canan, F.; Yildirim, O.; Cetin, M.M. Health-related quality of life in patients with anal fissure: Effect of type D personality. *Przegląd Gastroenterol.* **2014**, *9*, 93–98. [Google Scholar] [CrossRef]
34. Ortiz, H.; Marzo, J.; Armendariz, P.; De Miguel, M. Quality of life assessment in patients with chronic anal fissure after lateral internal sphincterotomy. *Br. J. Surg.* **2005**, *92*, 881–885. [Google Scholar] [CrossRef]
35. Trzpis, M.; Klaase, J.M.; Koop, R.H.; Broens, P.M.A. Fissurectomy combined with botulinum toxin A: A review of short- and long-term efficacy of this treatment strategy for chronic anal fissure; a consecutive proposal of a treatment algorithm for chronic anal fissure. *Coloproctology* **2020**, *42*, 400–408. [Google Scholar] [CrossRef]